AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01258634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Preoperative Chemotherapy Courses 1 and 3: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Poor Responders:~Course 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol
Study NCT01258634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: Preoperative Chemotherapy Courses 1, 2, 3, and 4: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000~Postoperative Chemotherapy for Poor Responders Courses 2, 4, and 5: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000
Study NCT01258634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PEG-filgrastim
Description: Preoperative Chemotherapy Courses 1, 2, 3, and 4: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 6mg; SQ starting 24 hours after chemotherapy
Study NCT01258634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide
Description: Preoperative Chemotherapy Courses 2 and 4: 50mg/m2 on days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 50mg/m2 on days 1, 2, 3, 4 Course 3: 50mg/m2 on days, 1, 2, 3, 4 Hour 0-1~Postoperative Chemotherapy for Poor Responders Course 4: 50mg/m2 on days 1, 2, 3, 4 Course 5: 50mg/m2 on days 1, 2, 3, 4
Study NCT01258634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ifosfamide
Description: Preoperative Chemotherapy Courses 2 and 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 3: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Poor Responders Course 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 5: 3g/m2; IV over 1 hour Days 1, 2, 3, 4
Study NCT03222089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 165 mg/m² 1-hour IV day 1
Study NCT03222089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m² 2-hours IV day 1
Study NCT03222089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m² 2-hours IV day 1
Study NCT03222089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoleucovorin
Description: Levoleucovorin 200 mg/m² 2-hours IV day 1
Study NCT03222089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levoleucovorin
Description: Levoleucovorin 200 mg/m² 2-hours IV day 1
Study NCT03222089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 2800 mg/m² 46-hours flat continuous infusion IV
Study NCT03222089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU 2800 mg/m² 46-hours flat continuous infusion IV
Study NCT03222089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF 150ug s.c. d3-7 , Repeated every 4 weeks.
Study NCT03222089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.
Study NCT01258634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: Preoperative Chemotherapy Courses 2 and 4: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Good Responders Courses 2 and 3: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Poor Responders Courses 4 and 5: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)
Study NCT04649840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Humoral and cellular immunity
Description: Humoral (IgG) and cellular (antigen-specific cells) immunity
Study NCT02049905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin
Study NCT02049905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
Study NCT04441528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lid wipes containing terpinen-4-ol and sodium hyaluronate
Description: Lid wipes will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
Study NCT04441528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baby shampoo
Description: Baby will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
Study NCT00044629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Insomnia
Study NCT00044629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia
Study NCT00044629 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Insomnia
Study NCT00044629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem tartrate (Ambien)
Study NCT00044629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02549287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare
Description: An evidence-based home visiting program
Study NCT01258634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Leucovorin
Description: Postoperative Chemotherapy for Poor Responders Courses 1 and 3: 15 mg/m2/dose IV or PO every 6 hours, beginning 24 hours after start of methotrexate infusion and continuing until methotrexate level is \<0.1 uM
Study NCT03819140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin
Description: Participants in each treatment arm will receive the medication Yasmin. However only the Cyclical OCP Therapy arm will take the sugar pills designated each month in the pill packs and the Continuous OCP Therapy arm will not.
Study NCT00689026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
Study NCT00689026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol with electrolytes
Description: Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.
Study NCT00689026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol with electrolytes
Description: Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.
Study NCT01552954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive education of low salt diet
Description: For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
Study NCT01383265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Water method and chromoendoscopy
Description: Study method will employ a 0.008% IC solution used with the water method for screening colonoscopy
Study NCT01383265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water method
Description: Control method will use plain water with water method for screening colonoscopy
Study NCT04000009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
Study NCT01579409 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PNNS guidelines
Description: Application of PNNS guidelines
Study NCT03654209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation
Description: APC will be applied to the perimeter of the resection site
Study NCT03654209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Snare Tip Soft Coagulation
Description: STSC will be applied to the perimeter of the resection site
Study NCT02062047 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: FMSRP
Description: FMSRP in a maximum of 24 hours.
Study NCT02701712 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic resonance - guided radiation therapy (MRgRT)
Description: Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
Study NCT01235403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide : 50 mg tablets bid. Titration phase: (12 weeks) 100 mg/day: duration 1 to 3 weeks. Then uptitration to optimal therapeutic dose of 200 mg/day to 400 mg/day, in steps of 100 mg/day and a time period per step of 1 to 3 weeks.~Maintenance phase (12 weeks): Optimal therapeutic dose 200 mg/day to 400 mg/day.~Taper phase if needed: 3 to 4 weeks
Study NCT03258749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: inhaled Tiotropium(18μg, qd)
Study NCT03258749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: inhaled formoterol(4.5μg, bid)
Study NCT02175355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of Micardis®
Study NCT02175355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of Micardis®
Study NCT02175355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of Micardis®
Study NCT02175355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Study NCT02175355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04173455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZ-A-018
Description: In the dose-escalation part, subjects will be assigned to five cohorts with increaing dose level to determine DLT and MTD during the first 28-day cycle.~In the expansion part, subjects will be assigned to two fixed dose corhort.
Study NCT01089231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
Study NCT01089231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (corn oil)
Description: corn oil (6 capsules per day)
Study NCT04838990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDSS
Description: Neurological Exam - EDSS (Expanded Disability Status Scale)
Study NCT04838990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDSS
Description: Neurological Exam - EDSS (Expanded Disability Status Scale)
Study NCT04838990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discussion of symptoms, Patient reported outcome (MSIS)
Description: Patients will be asked about their wellbeing
Study NCT04838990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion of symptoms, Patient reported outcome (MSIS)
Description: Patients will be asked about their wellbeing
Study NCT04183270 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: The survey will focus on non-valvular atrial fibrillation patients, who will start treatment with a NOAC, and their treating physician.
Study NCT03651050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith Based Outreach (FBO)
Description: Faith base outreach groups will be trained in P-MHDT
Study NCT03651050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community-health-workers (CHW)
Description: COmmon health workers will be trained in P-MHDT
Study NCT04064151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Guide
Description: 12-week long health promotion Smartphone application
Study NCT01764087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX2-391 and Paclitaxel
Description: A treatment cycle in phase I will consist of 28 days, according to the following schedule:~KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated~A treatment cycle in phase II will consist of 28 days, according to the following schedule:~KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.
Study NCT00286845 — intervention group
Intervention type: DRUG
Intervention: Standard Chemotherapy
Description: physician determined
Study NCT00627380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga lifestyle intervention
Description: Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.
Study NCT00627380 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
Study NCT01774513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procore-Needle
Study NCT02899494 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Antenatal classes
Study NCT02899494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical and psychic preparation
Study NCT04241094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loved one assisted treatment
Description: The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
Study NCT01610310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)
Description: 125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22
Study NCT02062047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMSRP
Description: FMSRP in a maximum of 24 hours.
Study NCT01610310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIIB017 (peginterferon beta-1a) Autoinjector
Description: 125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22
Study NCT02388802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte retrieval and freezing
Description: 10 Patients will undergo oocyte retrieval and freezing
Study NCT02388802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deceased Donor Allograft Excision
Description: Appropriately matched uterine transplant allografts will be excised from deceased donors
Study NCT02388802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Transplantation
Description: Following egg freezing the patients will undergo uterine transplant from deceased donors
Study NCT02388802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive Agents
Description: Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
Study NCT02388802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-vitro fertilisation
Description: 12 months after successful transplantation,the patients will undergo IVF
Study NCT02388802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caesarean Section
Description: Following successful conception and antenatal period, the babies will be born by Caesarean Section
Study NCT02432105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXE844 Sterile Otic Suspension, 0.3%
Study NCT02432105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tympanostomy Tube Insertion
Description: Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
Study NCT02432105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy Tube Insertion
Description: Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
Study NCT04232683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4Mg Capsule
Description: Tamsulosin given preoperatively to detect if rates of urinary retention after female pelvic floor surgeries are decreased
Study NCT04232683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo pill given preoperatively
Study NCT01256567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.
Study NCT01256567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m\^2) every 3 weeks.
Study NCT03275025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YRA-1909 low dose
Description: A low dose of YRA-1909; daily oral intake for 12 weeks
Study NCT03275025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YRA-1909 mid dose
Description: A mid dose of YRA-1909; daily oral intake for 12 weeks
Study NCT03275025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YRA-1909 high dose
Description: A high dose of YRA-1909; daily oral intake for 12 weeks
Study NCT03275025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosing with daily oral intake for 12 weeks
Study NCT03275025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo dosing with daily oral intake for 12 weeks
Study NCT03248258 — intervention group
Intervention type: OTHER
Intervention: Qualitative Interview or Focus group discussions
Description: The purpose of this study is to identify factors that influence decision-making in treatment selection and the optimal approach for sharing information about prognosis and guideline-based care.~Secondly, to further understand patient perspective on the concept of de-escalation, in which patients reduce the amount of chemotherapy to avoid side effects and (2) consider how prognosis would impact their decision-making about reducing chemotherapy (as standard or care or within a clinical trial).
Study NCT03133026 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single operator cholangioscopy, Endoscopic biliary RFA
Description: Single operator cholangioscopy will be done to acess the cause of occluded SEMS, if tumour ingrowth or overgrowth seen then endoscopic biliary RFA will be done
Study NCT01763710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel 80 mg/m2
Description: Paclitaxel 80 mg/m2 days 1, 8 and 15
Study NCT01763710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
Description: Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
Study NCT01763710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
Description: Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
Study NCT01763710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 150 mg/m2 days 1 and 15
Description: Nab-paclitaxel 150 mg/m2 days 1 and 15
Study NCT00316173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
Study NCT00316173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARBOPLATIN
Description: HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
Study NCT04127838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Occupational Therapy
Description: Occupational therapy may include methods to effectively modify environments (such as addition of task lighting), training in the use of assistive technology (such as voice activated devices), teaching new skills (such as sensory substitution) and prevention of accidents and injury (such as home safety modifications).
Study NCT00243880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovastatin
Description: investigators will treat the patients within 24 hours of symptom onset with short term high-dose lovastatin at escalating dosage. The escalating dosage levels will be 1, 3, 6, 8, and 10 mg/kg per day for 3 days.
Study NCT02568748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK
Description: Cytokine -induced killer cells in Egyptian patients with advanced hepatocellular carcinoma as treatment or adjuvant treatment in comparison with traditional treatment.
Study NCT02568748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Trans-arterial chemoembolization